Switchback from biosimilar tumor necrosis factor-alpha inhibitors to reference medicines: a review

Authors:

Abstract
1. Biologic therapies have been used successfully to treat many conditions, but are often associated with high costs due in part to the complexity of drug development [1,2]. After patent expiry and...
Funding Information
  • Sandoz/Hexal AG

This publication has 91 references indexed in Scilit: